Designer Enzyme to Fight HIV Shows Promise
Scientists in Germany have constructed a custom enzyme that reverses the process by which HIV inserts its genetic material into a CD4 cell's DNA, suggesting that treatment with similar enzymes could potentially rid infected cells of the virus.
June 26, 2007
Treatment Improves Survival Among IDUs Survival among HIV-infected intravenous drug users (IDUs) has improved dramatically since the introduction of combination antiretroviral therapy, with survival rates similar to HIV-negative IDUs.
Drug-Resistant HIV in Semen Stirs Concerns
Drug-resistant HIV can remain detectable in the male genital tract for an extended period of time, and potentially prolong the risk to sexual partners, according to a study published in the August 1 issue of the Journal of Infectious Disease.
June 21, 2007
Hep B and HIV Baraclude Users Beware Treating hepatitis B patients with the drug Baraclude® (entecavir) can cause those who are also infected with HIV to become resistant to two vital HIV drugs, according to a new report in the New England Journal of Medicine.
Panacos' Bevirimat Back on Track Panacos Pharmaceuticals reports that it is back on track with the development of its maturation inhibitor bevirimat (PA-457), after hitting a dosing snag reported in December 2006.
Several Factors Raise Women's Bone Loss Risk Decreased bone mineral density (BMD) is both highly prevalent and severe among underweight women with HIV and is associated with other factors like menstrual irregularities, reduced testosterone levels, lower lean body mass, and white race.
New Drugs Possible from Discovered HIV Transport System Likening HIV to “hobos on a train,” researchers at Johns Hopkins University School of Medicine have found that the virus uses a pre-existing transport system to leave one infected CD4 cell and move on to infect news ones.
June 05, 2007
Early Treatment may have CD4 Advantage The chances of achieving and maintaining a CD4 count of 800 or higher are best among those who start antiretroviral therapy early, according to new data from the ATHENA cohort study.
More Treatment News
Have news about HIV? Send press releases, news tips and other announcements to firstname.lastname@example.org.